Sentiss Pharma

What Sentiss Pharma does

Sentiss Pharma Private Limited is an India-based, founder-controlled niche pharmaceutical company founded in 1990 (originally as Promed Exports) by Deepak Bahri, focused on ophthalmic, inhalation (nebulization) and ENT (otic/nasal) pharmaceutical products. The company is headquartered in Gurgaon with its manufacturing plant in Nalagarh, Himachal Pradesh, employing 3,595+ people globally and serving prescription markets across 20+ countries including India, Russia, the USA, CIS, Central Asia and parts of Europe. Sentiss positions itself as a vertically integrated specialty pharma player, controlling the full value chain from formulation and analytical R&D (1,820 sq.m Sentiss Research Centre) through sterile manufacturing (four BFS lines plus three-piece bottle filling, 90 million units/year combined capacity) to commercial supply via wholly-owned subsidiaries and licensing partners.

The portfolio spans 100+ products covering dry eye, glaucoma, anti-infective, anti-inflammatory, ocular nutrition and mydriatic/cycloplegic ophthalmic indications, alongside nebulization and ENT formulations. Notable products include Irifrin (Phenylephrine), Signicef (Levofloxacin), Kombinil-Duo, Visallergol, Broxinac, Prolatan, Brinarga, On-Tears, Kitmox and Opacia. The company holds multiple granted patents in anti-glaucoma and anti-cataract formulations and allocates roughly 12% of its budget to R&D versus an industry standard of 6-7%. Manufacturing operations are differentiated by BFS sterile technology — Sentiss claims to be the first Indian company to introduce BFS-manufactured eye drops into the Russian market — combined with automated inspection and leak detection, supported by WHO-GMP, ISO 14001 and ISO 45001 certifications.

Commercially, Sentiss generates revenue through four principal streams: (i) branded and generic prescription product sales through its own subsidiaries in Russia and the USA, (ii) out-licensing of CTD dossiers (generics, 505(b)(2), Para IV) to distribution partners globally, (iii) contract manufacturing and technology transfer services from the Nalagarh facility, and (iv) in-licensing and co-marketing/co-development partnerships. Sentiss AG (Uster, Switzerland) operates as the global commercial hub for licensing and partnership activities, while Sentiss Rus LLC (Moscow) and Sentiss Pharmaceuticals LLC (San Clemente, CA) handle direct sales and distribution in the two largest single-country markets. Distribution beyond these geographies runs through licensing and supply partners using CTD dossiers. The company is privately held with no disclosed PE/VC investors and founder Deepak Bahri continues to serve as Managing Director.

Name

Sentiss Pharma

Legal name

Sentiss Pharma Private Limited

Website

https://sentisspharma.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sentiss Pharma is a private, India-based niche pharmaceutical company founded in 1990 that develops, manufactures and globally distributes prescription ophthalmic, inhalation and ENT products via BFS sterile manufacturing, wholly-owned subsidiaries and licensing partners across 20+ countries.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Ophthalmic & Otic Generics (HLAIABAF), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Ophthalmic pharmaceuticals
• Inhalation therapeutics
• ENT medications
• BFS sterile manufacturing
• Specialty pharma products

Headquarters

HQ city

Gurugram

HQ country

India

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (Prescription Pharmaceuticals): Sale of branded and generic ophthalmic, inhalation, ENT and specialty pharmaceutical products through own subsidiaries and distributor networks across global markets.
2. Out-licensing of Product Dossiers: Licensing of CTD dossiers for product development and supply, marketing and distribution in targeted geographies including generic products, CE Mark products, OTC products, and 505(b)(2) and Para IV products.
3. Contract Manufacturing and Technology Transfer: Technology development and transfer services through state-of-the-art manufacturing facility; specialized in solutions, suspensions, emulsions in unit-dose, multi-dose and preservative-free multi-dose containers.
4. In-Licensing and Co-Marketing: In-licensing of products for exclusive marketing in targeted geographies (Russia, CIS, India and other international markets), including co-marketing and co-development models with clinical trials.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Sentiss develops, manufactures and markets sterile prescription pharmaceutical products in three core therapy areas — ophthalmic (eye drops covering dry eye, glaucoma, anti-bacterial, anti-inflammatory, anti-infective, mydriatics, ocular nutrition and lubricants), inhalation/nebulization solutions and suspensions, and ENT (otic and nasal) drops — through its BFS and three-piece bottle filling lines at Nalagarh, India, distributing via wholly-owned subsidiaries in Russia and the USA and via licensing/distribution partners in other markets. In parallel it offers out-licensing of CTD dossiers, contract manufacturing and technology transfer, and in-licensing/co-marketing services.

Product overview

Sentiss Pharma is a niche pharmaceutical company that develops and markets a focused portfolio of ophthalmic, inhalation (nebulization), ENT, and specialty products. The company operates with a core competency in ophthalmics, offering treatments for Dry Eye, Glaucoma, Mydriatics, Anti-bacterial, Anti-inflammatory, Anti-infective, Ocular Nutritional Supplements, Local Anaesthetics, Ocular Lubricants, and Eye-Irrigation Solutions. Key ophthalmic products include Irifrin® (Phenylephrine), Signicef® (Levofloxacin), Kombinil-Duo® (Ciprofloxacin and Dexamethasone), Visallergol® (Olopatadine), Broxinac® (Bromfenac), Prolatan® (Latanoprost), Brinarga® (Brinzolamide and Timolol), On-Tears® (Carboxymethylcellulose), Kitmox® (Moxifloxacin), Opacia® (Travoprost), Activision® (Ocular Health Supplement), and DANCIL (Ofloxacin). The company controls its entire value chain from research and development through manufacturing and delivery to market, with manufacturing capabilities including Blow-Fill-Seal (BFS) technology and three-piece bottling lines at its Nalagarh facility.

Differentiator

Problem solved

Functional benefit

Brands

• Sentiss Foundation: Philanthropic arm of Sentiss Pharma focused on CSR activities including health, education, and environment programs under the SEVA initiative
• VisionEnvision

Products and services

• Irifrin® (Phenylephrine) ophthalmic solution Ophthalmic solution (mydriatic) used for pupil dilation in eye examinations and surgical procedures, sold as part of Sentiss's branded prescription ophthalmic portfolio through its own subsidiaries and distribution partners.
• Signicef® (Levofloxacin) ophthalmic solution Fluoroquinolone ophthalmic antibiotic solution for treating bacterial eye infections, part of Sentiss's branded prescription ophthalmic portfolio.
• Kombinil-Duo® (Ciprofloxacin and Dexamethasone) ophthalmic product Combination ophthalmic product combining the antibiotic Ciprofloxacin with the anti-inflammatory corticosteroid Dexamethasone, used to treat bacterial eye infections with associated inflammation.
• Visallergol® (Olopatadine) ophthalmic solution Ophthalmic antihistamine solution for treating allergic conjunctivitis and other eye allergies, part of Sentiss's branded prescription ophthalmic portfolio.
• Broxinac® (Bromfenac) ophthalmic solution Ophthalmic NSAID solution used to treat inflammation and pain following cataract surgery.
• Prolatan® (Latanoprost) ophthalmic solution Prostaglandin analog ophthalmic solution used to reduce intraocular pressure in glaucoma and ocular hypertension.
• Brinarga® (Brinzolamide and Timolol) ophthalmic combination Combination ophthalmic product containing a carbonic anhydrase inhibitor (Brinzolamide) and a beta-blocker (Timolol) for reducing intraocular pressure in glaucoma patients.
• On-Tears® (Carboxymethylcellulose) ocular lubricant Ocular lubricant eye drop based on Carboxymethylcellulose used to relieve symptoms of dry eye.
• Kitmox® (Moxifloxacin) ophthalmic solution Fluoroquinolone ophthalmic antibiotic solution (Moxifloxacin) for the treatment of bacterial eye infections.
• Opacia® (Travoprost) ophthalmic solution Prostaglandin analog ophthalmic solution (Travoprost) used to reduce intraocular pressure in the treatment of glaucoma.
• Activision® ocular health supplement Nutritional supplement formulated to support and maintain ocular health.
• DANCIL (Ofloxacin) ophthalmic/otic solution Ophthalmic and otic fluoroquinolone antibiotic solution (Ofloxacin) for treating bacterial eye and ear infections.
• Betaxolol Hydrochloride Ophthalmic Solution (Preservative Free) Preservative-free beta-blocker ophthalmic solution (Betaxolol) used for treating glaucoma and ocular hypertension.
• Timolol Maleate Ophthalmic Solution Beta-blocker ophthalmic solution (Timolol maleate) for reducing intraocular pressure in glaucoma patients.
• Ciprofloxacin Ophthalmic Solution Fluoroquinolone ophthalmic antibiotic solution (Ciprofloxacin) for treating bacterial keratitis and conjunctivitis.
• Out-licensing of pharmaceutical CTD dossiers Licensing of CTD dossiers for product development, supply, marketing and distribution in targeted geographies, offered to international pharmaceutical partners across generic, CE Mark, OTC, 505(b)(2) and Para IV product categories.
• Contract manufacturing and technology transfer services Contract manufacturing and technology development/transfer services offered to pharmaceutical partners globally using Sentiss's BFS and three-piece bottle filling lines, covering solutions, suspensions and emulsions in unit-dose, multi-dose and preservative-free multi-dose containers.
• In-licensing and co-marketing of pharmaceutical products In-licensing of pharmaceutical products for exclusive marketing by Sentiss in targeted geographies such as Russia, CIS, India and other international markets, including co-marketing and co-development models with clinical trials.

Quantifiable outcome

• 90 million units per annum combined manufacturing capacity across BFS and three-piece bottle lines
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• SADH Care HospitalcoreOthersNot-for-profit multispecialty hospital set up by Sentiss Foundation in January 2017 in Pataudi, Haryana. Provides sustainable quality healthcare services at highly subsidized rates with mother-and-child care facilities. Supported financially and administratively by Sentiss Foundation. Has completed 3,500+ minor surgeries, 610+ major surgeries, 56,000+ OPDs, 2,800+ in-patients served, and 489 baby deliveries.
• Niramaya Charitable TrustcoreOthersCSR partner for Project Drishti - monthly eye clinics for underprivileged people of Pataudi and remote villages around Nalagarh and Gurgaon. Has treated nearly 9,000 people, distributed 24,000 packs of medicine and 4,462 spectacles, and facilitated 820 free cataract surgeries.
• Amar Jyoti Charitable TrustminorOthersCSR partner for Project Roshni and Project Splash - supports orphaned and disabled children through art exhibitions and on-the-spot painting competitions. Sentiss invites children from Amar Jyoti School to sell handmade artifacts on festive occasions.
• Concern India FoundationminorOthersCSR partner for Project Splash - organizes and sponsors on-the-spot painting competition and day-out programs for differently abled children.
• Post Graduate Institute of Medical Sciences (PGIMS), ChandigarhminorOthersAssociation with PGIMS Chandigarh for annual blood donation drives at the manufacturing facility in Nalagarh. 192 units of blood donated in 2021 alone.
• IAMGURGAONminorOthersCSR partner for Project Go Green - monitoring tree plantation in Gurugram area. 5,100 saplings planted since 2011 with 80% survival rate monitored by IAMGURGAON team.
• Earth SaviorsminorOthersCSR partner for Project Sunset Joy and The Joy of Giving - volunteers spend time with homeless and elderly, and organize donations of clothes, footwear, school bags, toys and other useful items before Diwali.
• DeepashramminorOthersHome for disabled children where Sentiss Foundation set up a physiotherapy clinic in 2013. A qualified physiotherapist appointed by Sentiss Foundation provides regular physiotherapy sessions to help maintain mobility of children's limbs. Also supported through Project Sharing Happiness.
• Amba FoundationminorOthersLong-standing CSR partner for welfare work among communities. Partnership has continued through pandemic times supporting underserved communities.
• CanSupportminorOthersCSR partner for cancer awareness and fundraising. Sentiss support enables CanSupport to provide care and support to cancer patients and families.
• Strategic Distribution Partners (Other Markets)coreChannel Partner/ Reseller/ DistributorSentiss has developed CTD dossiers for licensing, distribution and supply across markets outside Russia, USA and India. Seeking potential partners for collaboration in respective markets. Partnering model includes exclusive marketing business model for targeted geographies, co-marketing and co-development models.
• Contract Manufacturing PartnerscoreChannel Partner/ Reseller/ DistributorThrough state-of-the-art manufacturing facility at Nalagarh, Sentiss manages technology development and transfer projects in collaboration with multiple customers. Offers end-to-end solutions from formulation development, analytical development, technology transfer, regulatory support, commercial supplies and logistics support.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Bausch + Lomb (Bausch Health): Global integrated ophthalmic health company with pharmaceutical, surgical and consumer vision products. Comparable to Sentiss in ophthalmic-only focus, Rx ophthalmics, and global distribution, but at vastly greater scale and brand recognition.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company by revenue with a broad specialty, generics and ophthalmic portfolio. Comparable to Sentiss in India manufacturing base and global commercialization, but vastly larger and more diversified — sets the upper-bound benchmark.
• Cipla Limited: Indian pharmaceutical major with strong inhalation/respiratory and specialty franchises and a growing ophthalmic presence. Comparable to Sentiss in India base, inhalation focus, and global emerging-market distribution model.
• Aurobindo Pharma: Indian vertically integrated generic pharmaceutical manufacturer with ophthalmic and sterile injectable offerings. Comparable to Sentiss in sterile manufacturing capability, US/EU regulatory footprint, and India-based cost structure.

Direct peers

• Ajanta Pharma: India-based specialty pharmaceutical company with a strong branded ophthalmic, dermatology and cardiac franchise across emerging markets. Closely comparable to Sentiss in India origin, niche specialty focus, emerging-market commercialization model, and multi-country subsidiary footprint.
• Santen Pharmaceutical: Japan-headquartered global ophthalmic specialty pharma pure-play with prescription Rx and surgical portfolios. Comparable to Sentiss as a pure ophthalmic specialist, but at much larger scale — useful upper benchmark for Sentiss's specialty ophthalmic trajectory.
• Théa Pharmaceuticals: European privately held ophthalmic specialty pharma company with strong preservative-free and dry-eye franchises. Comparable to Sentiss in private-company status, ophthalmic-only specialty focus, family/founder influence, and emphasis on formulation innovation.
• FDC Limited: Indian pharmaceutical company with a significant ophthalmic and ENT generics franchise marketed globally. Comparable to Sentiss in India manufacturing base, ophthalmic-otic product overlap, and exposure to both domestic and export channels.

Emerging players

• Nicox SA: French ophthalmic-focused specialty pharma company developing therapeutics for glaucoma and ocular surface diseases. Comparable niche focus on ophthalmic Rx, but smaller and earlier stage than Sentiss, making it a relevant scale/comparison reference.

Others

• Recipharm: Global contract development and manufacturing organization (CDMO) with sterile liquid and blow-fill-seal capabilities. Relevant as a peer for Sentiss's contract manufacturing and technology-transfer business line rather than as a direct competitor in branded ophthalmics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/sentisspharma
• LinkedInlinkedin.com/company/sentiss-pharma

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sentiss Pharma